OCT a good AMD screening tool

Article

Optical coherence tomography (OCT) is an effective screening tool for wet age-related macular degeneration (AMD).

Optical coherence tomography (OCT) is an effective screening tool for wet age-related macular degeneration (AMD), according to the results of a study published in the May issue of the British Journal of Ophthalmology.

James Talks and colleagues from the Royal Victoria Infirmary, Newcastle Upon Tyne, UK, carried out a retrospective audit of a consecutive series of 134 new patients referred with suspected wet AMD. If visual acuity (VA) was 6/60, an OCT was performed and if the OCT was consistent with wet AMD, the patient underwent simultaneous fundus fluorescein angiography (FFA) and indocyanine green angiography (ICGA). The number of additional diagnoses made using ICGA were recorded.

Twenty-three (17.16%) of the 134 patients had OCT only and were not found to have wet AMD. FFA and ICGA were performed in 111 patients, with 90 patients (81%) showing wet AMD.

OCT had a sensitivity, in this clinic, of 1 and a specificity of 0.65 for detecting wet AMD. ICGA provided additional diagnoses in 19 (14.17%) patients and detected specific vascular abnormalities in 58% of the occult lesions.

Although ICGA can provide an additional diagnosis it does not define vascular abnormalities in all occult cases. OCT, however, has proved to be an effective method of screening wet AMD.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
Related Content
© 2025 MJH Life Sciences

All rights reserved.